147 related articles for article (PubMed ID: 32372160)
1. Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals.
Blok JM; Meijer RP; van der Poel HG; Bex A; van Vooren J; van Urk JJ; Horenblas S; Bosch JLHR
World J Urol; 2021 Mar; 39(3):839-846. PubMed ID: 32372160
[TBL] [Abstract][Full Text] [Related]
2. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
[TBL] [Abstract][Full Text] [Related]
3. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
[TBL] [Abstract][Full Text] [Related]
4. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
5. Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience.
Kamel MH; Littlejohn N; Cox M; Eltahawy EA; Davis R
J Endourol; 2016 May; 30(5):510-9. PubMed ID: 26669219
[TBL] [Abstract][Full Text] [Related]
6. Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.
Gerdtsson A; Håkansson U; Törnblom M; Jancke G; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
Eur Urol Oncol; 2020 Jun; 3(3):382-389. PubMed ID: 31506250
[TBL] [Abstract][Full Text] [Related]
7. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications.
Cary C; Masterson TA; Bihrle R; Foster RS
Urol Oncol; 2015 Sep; 33(9):389.e15-21. PubMed ID: 25573056
[TBL] [Abstract][Full Text] [Related]
8. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer.
Hiester A; Nini A; Arsov C; Buddensieck C; Albers P
J Urol; 2020 Dec; 204(6):1242-1248. PubMed ID: 32717162
[TBL] [Abstract][Full Text] [Related]
9. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
10. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
Considine S; Heaney R; Conroy R; Thornhill JA
Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
[TBL] [Abstract][Full Text] [Related]
11. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.
Stepanian S; Patel M; Porter J
Eur Urol; 2016 Oct; 70(4):661-667. PubMed ID: 27068395
[TBL] [Abstract][Full Text] [Related]
12. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
Heidenreich A; Pfister D; Witthuhn R; Thüer D; Albers P
Eur Urol; 2009 Jan; 55(1):217-24. PubMed ID: 18926622
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.
Macleod LC; Rajanahally S; Nayak JG; Parent BA; Ramos JD; Schade GR; Holt SK; Dash A; Gore JL; Lin DW
Urology; 2016 May; 91():70-6. PubMed ID: 26802801
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
Djaladat H; Nichols C; Daneshmand S
Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
[TBL] [Abstract][Full Text] [Related]
15. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
17. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
18. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
19. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma.
Sharma P; Sverrisson EF; Zargar-Shoshtari K; Fishman MN; Sexton WJ; Dickinson SI; Spiess PE; Poch MA; Gilbert SM; Pow-Sang JM
Can J Urol; 2015 Aug; 22(4):7882-9. PubMed ID: 26267026
[TBL] [Abstract][Full Text] [Related]
20. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection.
Johnston P; Beck SD; Cheng L; Masterson TA; Bihrle R; Kesler K; Foster RS
J Urol; 2013 Sep; 190(3):874-7. PubMed ID: 23517745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
